This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Midtbø, K. Articles by Hals, O. Search for Related Content PubMed PubMed Citation Articles by Midtbø, K. Articles by Hals, O. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CHOLESTEROL VERAPAMIL HYDROCHLORIDE Medline Plus Health Information High Blood Pressure Social Bookmarking                         What's this?

No Metabolic Side Effects of Long-Term Treatment with Verapamil in Hypertension

From the Medical Department, Section of Cardiology, Ullevaal Hospital, Oslo, Norway

Oddveig Lauve

Ottar Hals

From Norsk Hydro Ltd., Oslo, Norway

In a prospective, open study 45 patients (mean age fifty-three years) with essential hypertension were treated with verapamil for four to eight years (mean 5.3 years). Blood pressure was satisfactorily controlled (from 160/104 to 145/91) and the side effects were infrequent, mild, and often transient. Verapamil did not exert any unfavorable metabolic or hematologic effects over the years. HDL-cholesterol was moderately increased (mean 24%) and the other plasma lipids were unaffected. These data suggest that the calcium channel blocker verapamil is a metabolically safe drug to use as monotherapy in essential hyper tension.

Angiology, Vol. 39, No. 12, 1025-1029 (1988)
DOI: 10.1177/000331978803901204


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?